Literature DB >> 12235090

Susceptibility to primary sclerosing cholangitis in Brazil is associated with HLA-DRB1*13 but not with tumour necrosis factor alpha -308 promoter polymorphism.

P L Bittencourt, S A Palacios, E L R Cançado, F J Carrilho, G Porta, J Kalil, A C Goldberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12235090      PMCID： PMC1773373          DOI： 10.1136/gut.51.4.609

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  12 in total

1.  Shared genetic risk factors in autoimmune liver disease.

Authors:  A J Czaja; P J Santrach; S Breanndan Moore
Journal:  Dig Dis Sci       Date:  2001-01       Impact factor: 3.199

2.  HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation.

Authors:  O Olerup; H Zetterquist
Journal:  Tissue Antigens       Date:  1992-05

3.  Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis.

Authors:  J M Farrant; D G Doherty; P T Donaldson; R W Vaughan; K M Hayllar; K I Welsh; A L Eddleston; R Williams
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

4.  Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP).

Authors:  M Bunce; G C Fanning; K I Welsh
Journal:  Tissue Antigens       Date:  1995-02

5.  HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis.

Authors:  W Z Mehal; Y M Lo; B P Wordsworth; J M Neuberger; S C Hubscher; K A Fleming; R W Chapman
Journal:  Gastroenterology       Date:  1994-01       Impact factor: 22.682

6.  HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis.

Authors:  O Olerup; R Olsson; R Hultcrantz; U Broome
Journal:  Gastroenterology       Date:  1995-03       Impact factor: 22.682

7.  Autoimmune hepatitis in Brazilian patients is not linked to tumor necrosis factor alpha polymorphisms at position -308.

Authors:  P L Bittencourt; S A Palácios; E L Cançado; G Porta; S Drigo; F J Carrilho; A A Laudanna; J Kalil; A C Goldberg
Journal:  J Hepatol       Date:  2001-07       Impact factor: 25.083

8.  Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2.

Authors:  P L Bittencourt; A C Goldberg; E L Cançado; G Porta; F J Carrilho; A Q Farias; S A Palacios; J M Chiarella; C P Abrantes-Lemos; V L Baggio; A A Laudanna; J Kalil
Journal:  Am J Gastroenterol       Date:  1999-07       Impact factor: 10.864

9.  Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis.

Authors:  W Bernal; M Moloney; J Underhill; P T Donaldson
Journal:  J Hepatol       Date:  1999-02       Impact factor: 25.083

10.  Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology.

Authors:  R W Chapman; B A Arborgh; J M Rhodes; J A Summerfield; R Dick; P J Scheuer; S Sherlock
Journal:  Gut       Date:  1980-10       Impact factor: 23.059
View more
  9 in total

1.  Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations.

Authors:  Christopher L Bowlus; Chin-Shang Li; Tom H Karlsen; Benedicte A Lie; Carlo Selmi
Journal:  Liver Transpl       Date:  2010-11       Impact factor: 5.799

2.  Human leucocyte antigens and pediatric autoimmune liver disease: diagnosis and prognosis.

Authors:  Norman Junge; Miriam Tiedau; Murielle Verboom; Michael Hallensleben; Rainer Blasczyk; Jerome Schlue; Imeke Goldschmidt; Eva-Doreen Pfister; Ulrich Baumann
Journal:  Eur J Pediatr       Date:  2015-11-14       Impact factor: 3.183

3.  The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population.

Authors:  Elaine Toy; Sripriya Balasubramanian; Carlo Selmi; Chin-Shang Li; Christopher L Bowlus
Journal:  BMC Gastroenterol       Date:  2011-07-18       Impact factor: 3.067

Review 4.  Pathogenesis of primary sclerosing cholangitis.

Authors:  Marion J Pollheimer; Emina Halilbasic; Peter Fickert; Michael Trauner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-12       Impact factor: 3.043

Review 5.  The Role of Genetic and Immune Factors for the Pathogenesis of Primary Sclerosing Cholangitis in Childhood.

Authors:  Priscila Menezes Ferri; Ana Cristina Simões E Silva; Soraya Luiza Campos Silva; Diego Junior Queiroga de Aquino; Eleonora Druve Tavares Fagundes; Débora Marques de Miranda; Alexandre Rodrigues Ferreira
Journal:  Gastroenterol Res Pract       Date:  2016-11-02       Impact factor: 2.260

6.  A novel prognostic model for transplant-free survival in primary sclerosing cholangitis.

Authors:  Elisabeth M de Vries; Junfeng Wang; Ronald B Geskus; Cyriel Y Ponsioen; Kate D Williamson; Mariska M Leeflang; Kirsten Boonstra; Rinse K Weersma; Ulrich Beuers; Roger W Chapman
Journal:  Gut       Date:  2017-07-24       Impact factor: 23.059

7.  Antineutrophil cytoplasmic antibody profiles differ according to type of primary sclerosing cholangitis and autoimmune hepatitis.

Authors:  Juliana Goldbaum Crescente; Alessandra Dellavance; Marcio Augusto Diniz; Flair Jose Carrilho; Luis Eduardo Coelho de Andrade; Eduardo Luiz Rachid Cançado
Journal:  Clinics (Sao Paulo)       Date:  2021-02-05       Impact factor: 2.365

Review 8.  The immunobiology of primary sclerosing cholangitis.

Authors:  Jonathan H Aron; Christopher L Bowlus
Journal:  Semin Immunopathol       Date:  2009-05-26       Impact factor: 9.623

9.  Lack of evidence for association of primary sclerosing cholangitis and primary biliary cirrhosis with risk alleles for Crohn's disease in Polish patients.

Authors:  Pawel Gaj; Andrzej Habior; Michal Mikula; Jerzy Ostrowski
Journal:  BMC Med Genet       Date:  2008-08-21       Impact factor: 2.103
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.